In-Class Transition (iCT) of Proteasome Inhibitor-Based Therapy Prolongs Progression-Free Survival in High-Risk Myeloma Patients: A Real-World Chinese Cohort Study
机构：[1]Tianjin Key Lab Ophthalmol & Visual Sci, Tianjin, Peoples R China[2]Tianjin Med Univ Gen Hosp, Dept Hematol, Tianjin, Peoples R China[3]Tianjin Inst Hematol, Tianjin, Peoples R China[4]Tianjin Med Univ, Gen Hosp, Tianjin, Peoples R China[5]Capital Med Univ, Beijing Chaoyang Hosp, Beijing, Peoples R China北京朝阳医院[6]Capital Med Univ, Sch Publ Hlth, Beijing, Peoples R China[7]Henan Prov Peoples Hosp, Dept Hematol, Zhengzhou, Peoples R China[8]Peking Union Med Coll Hosp, Dept Hematol, Beijing, Peoples R China[9]Beijing Jishuitan Hosp, Dept Hematol, Beijing, Peoples R China[10]China Japan Friendship Hosp, Beijing, Peoples R China[11]Hebei Med Univ, Hosp 4, Hebei Tumor Hosp, Shijiazhuang, Peoples R China河北医科大学第四医院[12]Hebei Univ, Afliated Hosp, Baoding, Peoples R China[13]Shanxi Med Univ, Hosp 2, Dept Hematol, Taiyuan, Peoples R China[14]Inner Mongolia Med Univ, Afliated Hosp, Hohhot, Peoples R China[15]Inner Mongolia Autonomous Reg Peoples Hosp, Hohhot, Peoples R China[16]Handan Cent Hosp, Dept Hematol, ,China, Handan, Hebei, Peoples R China[17]China Med Univ, Shengjing Hosp, Dept Hematol, Shenyang, Peoples R China中国医科大学附属盛京医院中国医科大学盛京医院[18]Jilin Univ, China Japan Union Hosp, Changchun, Peoples R China吉林大学中日联谊医院
第一作者机构：[1]Tianjin Key Lab Ophthalmol & Visual Sci, Tianjin, Peoples R China[2]Tianjin Med Univ Gen Hosp, Dept Hematol, Tianjin, Peoples R China[3]Tianjin Inst Hematol, Tianjin, Peoples R China
推荐引用方式(GB/T 7714)：
Fu Rong,Yu Hong,Liu Aijun,et al.In-Class Transition (iCT) of Proteasome Inhibitor-Based Therapy Prolongs Progression-Free Survival in High-Risk Myeloma Patients: A Real-World Chinese Cohort Study[J].BLOOD.2024,144:7846-7847.doi:10.1182/blood-2024-209471.
APA：
Fu, Rong,Yu, Hong,Liu, Aijun,Hou, Rui,Zhu, Zunmin...&Chen, Wenming.(2024).In-Class Transition (iCT) of Proteasome Inhibitor-Based Therapy Prolongs Progression-Free Survival in High-Risk Myeloma Patients: A Real-World Chinese Cohort Study.BLOOD,144,
MLA：
Fu, Rong,et al."In-Class Transition (iCT) of Proteasome Inhibitor-Based Therapy Prolongs Progression-Free Survival in High-Risk Myeloma Patients: A Real-World Chinese Cohort Study".BLOOD 144.(2024):7846-7847
医学